Search Congress
Bills
25Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
Appropriates FY2026 funding for USDA, the Food and Drug Administration, and related agencies, while setting limits and conditions on the use of those funds
Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027
Funds USDA, the Food and Drug Administration, and related agencies for FY2027 while setting conditions on the use of appropriated funds
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
Appropriates FY2026 funding for USDA, the Food and Drug Administration, rural development, nutrition assistance, and related agricultural agencies, while setting conditions on use of those funds
Full-Year Continuing Appropriations and Extensions Act, 2025
Provides full-year FY2025 continuing appropriations for federal agencies and extends multiple expiring health and other federal programs and authorities through FY2025
Continuing Appropriations Act, 2027
Continues FY2027 appropriations for federal agencies through early December 2026 or until regular appropriations are enacted, while extending several expiring programs and authorities
Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026
Extends continuing appropriations for agriculture, the legislative branch, and military construction and veterans affairs, while continuing related extensions for fiscal year 2026
Continuing Appropriations and Extensions Act, 2027
Continues FY2027 funding for federal agencies through December 11, 2026 or until regular appropriations are enacted, while extending multiple expiring federal programs and authorities
Continuing Appropriations and Extensions and Other Matters Act, 2026
Provides continuing fiscal year 2026 funding for federal agencies, permanently extends expanded health insurance tax credits, and extends several expiring programs and authorities
Continuing Appropriations and Extensions and Other Matters Act, 2026
Extends FY2026 federal funding through a short-term continuing resolution while permanently extending expanded health insurance premium tax credits and continuing several expiring programs
Consolidated Appropriations Act, 2026
Funds multiple federal departments and agencies for the rest of FY2026, continues Homeland Security funding temporarily, and extends several expiring federal programs and authorities
Recognizing the history of the drug diethylstilbestrol and the harm it has caused, and for other purposes.
Recognizes the history of diethylstilbestrol and the harm the drug has caused to affected people
To prohibit the use of Federal funds to implement, administer, or enforce a final rule of the Food and Drug Administration relating to "Medical Devices; Laboratory Developed Tests", and for other purposes.
Prohibits federal funding to carry out or enforce the FDA laboratory developed tests rule treating certain tests as regulated medical devices
Prescription Freedom Act of 2025
Eliminates FDA authority to require prescription-only dispensing for most drugs while keeping that authority for drugs intended to terminate a pregnancy
HEALTH Act
Establishes a new House Committee on Health and shifts jurisdiction over biomedical research, public health, and federally supported health care matters to it
Right to Treat Act
Authorize terminally ill patients to access personalized investigational treatments based on their own genetic and molecular profile
Interagency Patent Coordination and Improvement Act of 2025
Establishes an interagency patent task force to coordinate USPTO and FDA work on patents for human drugs and biological products
SAFE Drugs Act of 2026
Increases oversight of drug compounding by tightening statutory limits on compounded copies of commercially available drugs and adding reporting and inspection requirements
Stop STALLING Act
Prohibits objectively baseless FDA citizen petitions used to delay competing drug approvals and treats them as unfair competition in the generic drug market
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
Reauthorizes through FY2031 and revises federal ALS and rare neurodegenerative disease therapy research programs, including grant conditions, FDA planning, and impact reporting
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
Reauthorizes through FY2031 and revises federal ALS and neurodegenerative disease therapy programs, including grant oversight and FDA planning for investigational drug development and access
Mikaela Naylon Give Kids a Chance Act
Expand FDA authority over rare pediatric disease research by strengthening pediatric study enforcement, renewing pediatric incentives and funding, and clarifying orphan drug exclusivity rules
Better FDA Act of 2025
Establishes reforms to improve Food and Drug Administration operations and oversight in 2025
Right to FDA-Approved Medicines Act
Establishes a right to obtain medicines that have been approved by the Food and Drug Administration
To provide the Food and Drug Administration needed authorities to carry out its regulatory mission with respect to human foods, to provide additional resources and authorities with respect to human foods research, and for other purposes.
Authorize new Food and Drug Administration powers and resources to regulate human foods and conduct human foods research
To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes.
Nullifies the FDA's January 2023 mifepristone REMS changes and bars similar future changes to dispensing requirements for the abortion pill